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Abstract
Background: There is an urgent need for developing objective, effective and convenient measurements to help
clinicians accurately identify bradykinesia. The purpose of this study is to evaluate the accuracy of an objective
approach assessing bradykinesia in finger tapping (FT) that uses evolutionary algorithms (EAs) and explore whether
it can be used to identify early stage Parkinson’s disease (PD).
Methods: One hundred and seven PD, 41 essential tremor (ET) patients and 49 normal controls (NC) were recruited.
Participants performed a standard FT task with two electromagnetic tracking sensors attached to the thumb and index
finger. Readings from the sensors were transmitted to a tablet computer and subsequently analyzed by using EAs. The
output from the device (referred to as "PD-Monitor") scaled from − 1 to + 1 (where higher scores indicate greater
severity of bradykinesia). Meanwhile, the bradykinesia was rated clinically using the Movement Disorder Society-
Sponsored Revision of the Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) FT item.
Results: With an increasing MDS-UPDRS FT score, the PD-Monitor score from the same hand side increased
correspondingly. PD-Monitor score correlated well with MDS-UPDRS FT score (right side: r = 0.819, P = 0.000;
left side: r = 0.783, P = 0.000). Moreover, PD-Monitor scores in 97 PD patients with MDS-UPDRS FT bradykinesia
and each PD subgroup (FT bradykinesia scored from 1 to 3) were all higher than that in NC. Receiver operating characteristic
(ROC) curves revealed that PD-Monitor FT scores could detect different severity of bradykinesia with high accuracy (≥89.7%)
in the right dominant hand. Furthermore, PD-Monitor scores could discriminate early stage PD from NC, with area under the
ROC curve greater than or equal to 0.899. Additionally, ET without bradykinesia could be differentiated from PD by
PD-Monitor scores. A positive correlation of PD-Monitor scores with modified Hoehn and Yahr stage was found in the
left hand sides.
Conclusions: Our study demonstrated that a simple to use device employing classifiers derived from EAs could not
only be used to accurately measure different severity of bradykinesia in PD, but also had the potential to differentiate
early stage PD from normality.
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Background
Parkinson’s disease (PD) is the second most common neu-
rodegenerative disorder and is characterized by bradykine-
sia, resting tremor and rigidity. It has affected
approximately 1.7% of the population over 65 years old in
China and has a profound impact on the patients’ daily
lives [1]. Although currently there is no cure for PD, the
correct diagnosis is important not only for the treatment
and prognosis, but also for clinical trials and epidemio-
logical studies. However, practically misdiagnosis of PD is
much common. A recent review evaluated the accuracy of
clinical diagnosis of PD reported in the last 25 years and
found that it was only 80.6% [2]. Accuracy has not signifi-
cantly improved in the last 25 years, particularly in the
early stages of the disease. Essential tremor (ET) is one of
the conditions most easily confused with PD, especially in
their early stages where clinical signs are subtle [3]. Al-
though various types of tremors are the major clinical
overlaps between these two disease entities, a number of
ET patients also present with bradykinesia and gait dis-
turbance mimicking the symptoms of PD [4, 5].
Bradykinesia is the prerequisite for PD diagnosis [6],
which makes accurate identification of bradykinesia piv-
otal. It can be evaluated by a neurologist’ subjective judg-
ment of several tasks, such as finger tapping (FT), hand
movements, pronation-supination movements, toe tapping
and foot tapping [7]. Unfortunately, bradykinesia-related
items have the lowest reliability among all Unified Parkin-
son’s Disease Rating Scale (UPDRS) III items (motor evalu-
ation), particularly when the severity is slight or mild [8].
Therefore, there is an urgent need to develop objective, ef-
fective and convenient measurements to help clinicians ac-
curately identify bradykinesia, which can potentially lead to
earlier diagnosis of PD.
Recently, a United Kingdom (UK)-based research group
has developed a system called PD-Monitor that employs
the evolutionary algorithm (EA, a form of artificial
intelligence) to induce classifiers capable of recognizing
bradykinesia in PD patients when performing FT tasks [9].
The aim of this study was to a) validate the accuracy of
the EA to assess bradykinesia of FT in a Chinese cohort,
b) examine the ability of the EA to distinguish early stage
PD patients, and c) explore whether the EA scores related
with disease severity.
Subjects and methods
Subjects
A total of 107 PD patients, 41 ET patients and 49 age and
gender matched normal controls (NC) participated in this
study. Normal controls were recruited from patients’
spouses and companions. In order to rule out data bias
due to dominant hand difference, all selected participants
were right-hand dominant. The diagnosis of PD or ET
was confirmed by two or more experienced movement
disorder specialists, according to the MDS clinical diag-
nostic criteria for PD [6] and diagnostic criteria for ET [10].
Exclusion criteria included: cognitive impairment (Mini
Mental State Examination (MMSE) < 24 [11]), clinically de-
fined fracture or arthritis of an upper limb, and other cen-
tral nervous system diseases that might affect hand
flexibility. All the PD patients were treated with
anti-parkinsonism medication and at “on” medication sta-
tus when assessed except for 17 de novo patients. There
were 10 PD patients whose FT bradykinesia was not obvi-
ous and scored zero when they were at “on” medication
status. They were only included in the evaluation of the
correlation between PD-Monitor FT objective score and
MDS-UPDRS FT subjective score. The study was approved
by the Ethics Committee of Ruijin Hospital, Shanghai Jiao
Tong University School of Medicine. Written informed
consents were obtained from all the participants.
Methods
Demographic data and medical history were collected
from all participants. Cognitive function was evaluated
using the MMSE [12] and disease severity was evaluated
using the modified Hoehn and Yahr (H-Y) scale [13].
The total daily dose of dopaminergic medications in
each patient was determined by means of L-dopa
equivalent daily dose (LEDD, mg/day) based on theoret-
ical equivalence as previously reported [14].
Assessment of finger-tapping
FT data were collected using two small, simple and
non-invasive sensors which were attached to the sub-
ject’s thumb and index finger while performing FT tasks
(Fig. 1a). The sensors have a sampling rate of 60 Hz, and
measure both position and orientation relative to a point
source in real time. Readings from the sensors are trans-
mitted to a tablet computer and then analyzed by the spe-
cialist software employing EA. These algorithms have
been trained to recognize PD patients’ movements charac-
teristic of bradykinesia [9]. The calculated value based on
the FT movement pattern is then presented on the tablet,
using an objective score scaled from − 1 to + 1 (where
higher scores indicate greater severity of bradykinesia).
The EA device is referred as “PD-Monitor” hereafter.
Finger Tapping: FT is a standard clinical test for evalu-
ating bradykinesia. The subjects were asked to bend
their elbow and raise their hand, making sure that the
arm was unsupported. They were then instructed to tap
their thumb and index finger repeatedly for 30 s as rap-
idly as possible, separating the finger and thumb as far
as possible [9]. They were allowed to rest for 1 min be-
fore repeating the task with the same hand. The larger
PD-Monitor score of the two exercises was used for fur-
ther statistical analysis. FT data were recorded from each
hand. Figure 1b illustrated the finger tapping process,
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and Fig. 1c showed the example data acquired from two
patients, presented graphically as the acceleration of the
fingers over the duration of the FT task.
Movement Disorder Society-sponsored revision of the
UPDRS (MDS-UPDRS) Ratings: During FT tasks, the bra-
dykinesia of both hands were independently rated by two
neurologists who were blinded to the PD-Monitor score
using the “finger-tapping” item of the MDS-UPDRS III
(item 3.4). FT was scored from 0 to 4. Zero corresponds
to normal action and 4 indicates that the task could hardly
be performed [7]. Rating discrepancies were discussed be-
tween the raters, and then settled by an agreed score. We
used the MDS-UPDRS FT score (item 3.4) as a gold
standard for abnormality or slowness of FT.
Evolutionary algorithms
EAs are a form of artificial intelligence that provide a
generic method for optimizing classifier models to fit
data. The algorithm refines a population of classifiers
through a repeated process of variation and selection in-
spired by the theory of Darwinian evolution. Selection is
based on maximizing fitness criteria, the area under the
receiver operating characteristic (ROC) curve (AUC),
when discriminating the FT movements of PD patients
from NC in a training data set. These movement record-
ings were gathered during a clinical study held at a neur-
ology center in the UK [9, 15]. EAs are stochastic,
meaning that different solutions are found each time the
algorithm is executed. To address this, the best perform-
ing classifier is selected from 50 repeated runs of the al-
gorithm. A classifier takes the form of a symbolic
equation that is applied to a movement data sequence
using a standard sliding window approach. Inputs to the
classifier are the individual accelerations within each
window. The output of the classifier is the mean of the
symbolic equation’s output across all windows in a se-
quence. Full details of the implementation of the algo-
rithm can be found in M. A. Lones et al.’s research [9].
Statistical analysis
The statistical analyses were conducted using SPSS soft-
ware v.22.0 [16]. Data were expressed as numbers or as
Fig. 1 Schematic representations of sensors and finger tapping task. a Sensors attached to nail bed of index finger and thumb. b Opening and
closing phases of the finger tapping task. c Example data from two patients showing acceleration of fingers during the finger tapping task
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mean ± SE. Nonparametric Kruskal-Wallis one-way analysis
of variance with post hoc tests as needed were used in all
data analysis procedures. Mann-Whitney U test and the
Chi-squared test were used for continuous variables or cat-
egorical variables. ROC curves were constructed using
PD-Monitor scores from PD and NC. Spearman rank-order
correlation was used to evaluate the association. Partial cor-
relation was used to further examine the correlation of
PD-Monitor score and modified H-Y stage after controlling
age, gender, disease duration and LEDD. The limit of signifi-
cance was set at P < 0.05 (two-tailed).
Results
PD-monitor FT objective score correlated well with the
MDS-UPDRS FT subjective score
The ability of the EA to detect bradykinesia and its se-
verity was assessed in 107 PD patients and 49 NC.
Demographic and clinical data of all participants were
demonstrated in Table 1. All the subjects were classified
into four subgroups according to their MDS-UPDRS FT
grade from 0 to 3 (no patient scored 4 in our study). A
total of 312 assessments of both hands were recorded,
where 65 of the PD FT assessments were scored 0, 49
scored 1, 63 scored 2, and 37 scored 3, and all 98 of the
NC FT assessments were scored 0.
It demonstrated that with an increasing MDS-UPDRS FT
score, the PD-Monitor score from the same hand side in-
creased correspondingly (right side: 0: − 0.23 ± 0.03; 1: 0.17
± 0.04; 2: 0.32 ± 0.03; 3: 0.46 ± 0.04, P = 0.000; left side: 0: −
0.17 ± 0.03; 1: 0.12 ± 0.03; 2: 0.33 ± 0.02; 3: 0.56 ± 0.03,
P = 0.000). Post hoc tests revealed a significant difference in
PD-Monitor score between subjects with FT scored 0 and
other subgroups (all with P = 0.000) for the right sides. For
the left sides, the significant difference was also found be-
tween subjects with FT scored 0 and other subgroups (all
with P ≤ 0.002), and between subjects with FT scored 1
and 2 (P = 0.046), or 3 (P = 0.000). Spearman rank-order
correlation analysis further revealed that the
Table 1 Demographic and clinical data of the study
participants
PD NC ET P value
Overall subjects
Number N = 107 N = 49 N = 41
Gender[male/female] 48/59 18/31 18/23 0.625
Age[years] 62.1 ± 0.8 61.9 ± 1.2 60.0 ± 1.9 0.515
Disease duration[years] 5.0 ± 0.4 NA 9.8 ± 1.3 0.003**
LEDD (mg) 311.2 NA NA
Subjects with right affected side
Number N = 74 N = 49
Gender[male/female] 33/41 18/31 0.386
Age[years] 62.4 ± 1.0 61.9 ± 1.2 0.662
Subjects with left affected side
Number N = 75 N = 49
Gender[male/female] 32/43 18/31 0.510
Age[years] 62.8 ± 1.0 61.9 ± 1.2 0.490
Subgroup of PD (FT = 1) vs.NC
Subjects with right affected side
Number N = 19 N = 49
Gender[male/female] 7/12 18/31 0.993
Age[years] 61.9 ± 2.1 61.9 ± 1.2 0.995
Subjects with left affected side
Number N = 30 N = 49
Gender[male/female] 13/17 18/31 0.560
Age[years] 62.3 ± 1.7 61.9 ± 1.2 0.705
Subgroup of PD (FT = 2) vs.NC
Subjects with right affected side
Number N = 38 N = 49
Gender[male/female] 18/20 18/31 0.318
Age[years] 63.6 ± 1.3 61.9 ± 1.2 0.389
Subjects with left affected side
Number N = 25 N = 49
Gender[male/female] 8/17 18/31 0.687
Age[years] 66.1 ± 1.5 61.9 ± 1.2 0.051
Subgroup of PD (FT = 3) vs.NC
Subjects with right affected side
Number N = 17 N = 49
Gender[male/female] 8/9 18/31 0.453
Age[years] 60.5 ± 2.3 61.9 ± 1.2 0.809
Subjects with left affected side
Number N = 20 N = 49
Gender[male/female] 11/9 18/31 0.163
Age[years] 59.4 ± 1.7 61.9 ± 1.2 0.334
Subgroup of PD (H-Y = 1) vs.NC
Subjects with right affected side
Table 1 Demographic and clinical data of the study
participants (Continued)
PD NC ET P value
Number N = 18 N = 49
Gender[male/female] 8/10 18/31 0.566
Age[years] 60.2 ± 2.0 61.9 ± 1.2 0.457
Subjects with left affected side
Number N = 18 N = 49
Gender[male/female] 8/10 18/31 0.566
Age[years] 59.3 ± 1.9 61.9 ± 1.2 0.311
Kruskal-Wallis test and Mann-Whitney U test were used to compare the
continuous variables. The Chi-square test was used to compare the categorical
variables. Data were expressed as numbers or as mean ± SE. ** P < 0.01
PD Parkinson’s disease, ET essential tremor, NC normal controls, H-Y modified
Hoehn and Yahr stage, LEDD levodopa equivalent daily dose, NA not available
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PD-Monitor score correlated well with MDS-UPDRS
FT score (right side: r = 0.819, P = 0.000; left side:
r = 0.783, P = 0.000, see Fig. 2).
PD-monitor FT objective score detected different severity
of bradykinesia
There were 10 out of 107 PD patients whose FT brady-
kinesia of both hands was not obvious and scored zero
when assessed at ‘on’ medication status, and they were
excluded for the further analysis. The remaining 97 PD
were further classified into different subgroups based on
their MDS-UPDRS FT scores and affected hand sides.
Seventy-four PD patients exhibited detectable bradykine-
sia with their right hands, among them 19 were scored
1, 38 scored 2 and 17 scored 3. For the left hands, 75 pa-
tients showed detectable bradykinesia, among them 30
were scored 1, 25 scored 2 and 20 scored 3. The overall
97 PD patients and the different subgroups (FT = 1, FT
= 2 and FT = 3) were compared with 49 age and gender
matched NC with their same hand sides, respectively.
Clinical and demographic data of subjects were shown
in Table 1.
It demonstrated that PD-Monitor scores in overall PD
patients and each PD subgroup were all higher than that
in NC (right affected side: 0.31 ± 0.02, 0.17 ± 0.04, 0.32 ±
0.03, 0.46 ± 0.04 vs. -0.24 ± 0.03, all with P ≤ 0.001; left
affected side: 0.31 ± 0.03, 0.12 ± 0.03, 0.33 ± 0.02, 0.56 ±
0.03 vs. -0.27 ± 0.04, all with P = 0.000).
The ROC curves illustrated strong separation between
overall PD and NC, as well as between each subgroup of
PD and NC (Table 2), with AUC values of 0.976, 0.952,
0.979, 0.995 (all with P = 0.000) for the right affected
sides (Fig. 3a) and AUC values of 0.959, 0.898, 0.996,
1.000 (all with P = 0.000) for the left affected sides
(Fig. 3b). For the right affected side, cutoff values of
0.018, 0.005, 0.118 or 0.122 could discriminate corre-
sponding groups of PD from NC with 93.5%, 89.7%,
94.3% or 98.5% of accuracy, 94.6, 94.7, 89.5% or 100% of
sensitivity and 91.8, 89.8, 98.0% or 98.0% of specificity
(Fig. 3a). For the left affected side, cutoff values of 0.072,
0.060, 0.122 or 0.308 could discriminate corresponding
groups of PD from NC with 88.6, 81.0, 97.3% or 100% of
accuracy, 85.1, 65.5, 96.0% or 100% of sensitivity and
91.8, 89.8, 98.0% or 100% of specificity (Fig. 3b).
PD-monitor FT objective score could be used for early
diagnosis of PD
In order to identify whether the PD-Monitor FT object-
ive score could potentially discriminate early stage PD
from NC, we compared FT scores of 36 early stage PD
patients (whose H-Y stage was 1 and FT score above 0)
with 49 age and gender matched NC (Table 1). It turned
out that PD-Monitor scores were significantly higher in
early PD patients than that in NC (right affected side:
0.28 ± 0.05 vs.-0.24 ± 0.03, P = 0.000; left affected side:
0.21 ± 0.06 vs. -0.27 ± 0.04, P = 0.000). The ROC curves
illustrated a strong separation between the early PD pa-
tients and NC (Table 2), with an AUC of 0.963
(P = 0.000) equivalent to accuracy/sensitivity/specificity
of 92.5%/94.4%/91.8% at the cutoff value of 0.029 for the
right affected side, and an AUC of 0.899 (P = 0.000)
equivalent to accuracy/sensitivity/specificity of 89.6%/
66.7%/98.0% at the cutoff value of 0.141 for the left
affected side (Fig. 4).
PD-monitor FT objective scores could differentiate ET
without bradykinesia from PD
Forty-one ET patients were recruited in the present
study. Ten ET patients were rated as 1 with
MDS-UPDRS FT in either right or left or both hands,
where 7 were scored 1 in the right hands, and 6 were
scored 1 in the left hands. Using the cutoff values for
discriminating overall PD from NC, that is 0.018 for the
right side and 0.072 for the left side, 87.1% (27/31) ET
without bradykinesia were differentiated from PD in the
right side hands with 94.6% of specificity and 92.4% of
accuracy; while 90.3% (28/31) ET without bradykinesia
were differentiated from PD in the left side hands with
85.3% of specificity and 86.8% of accuracy. However, for
those ET with MDS-UPDRS FT scored 1, 5 out of 7
Fig. 2 PD-Monitor FT objective score correlated well with the MDS-
UPDRS FT subjective score. Spearman rank-order correlation analysis
revealed that the PD-Monitor score positively correlated with MDS-
UPDRS FT score. Right side: r = 0.819, P = 0.000. Left side: r = 0.783, P =
0.000. MDS-UPDRS, Movement Disorder Society-sponsored revision of
the Unified Parkinson’s disease rating scale; FT, finger tapping
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(71.4%) or 3 out of 6 (50.0%) were recognized as object-
ive bradykinesia in the right or left hand sides, indicating
that they could not be differentiated from PD
bradykinesia.
The relationship between PD-monitor FT objective score
and disease severity
Modified H-Y staging was used to classify PD patients
into three subgroups. For the right affected side, 18 PD
patients were at H-Y stage 1, but assigned as H-Y 1–1.5,
28 were at H-Y 2–2.5, and 5 were at H-Y 3–4. For the
left affected side, 18 were at H-Y stage 1, 27 were at H-Y
2–2.5, and 9 were at H-Y 3–4.
Results showed that the PD-Monitor score gradually
increased as modified H-Y stage increased in both af-
fected hand sides (right affected side: 0.28 ± 0.05 in H-Y
1–1.5 vs. 0.34 ± 0.04 in H-Y = 2–2.5 vs. 0.41 ± 0.07 in
H-Y = 3–4, P = 0.583; left affected side: 0.21 ± 0.06 in
H-Y 1–1.5 vs. 0.35 ± 0.04 in H-Y = 2–2.5 vs. 0.52 ± 0.05
in H-Y = 3–4, P = 0.007). However, the significance was
only achieved between H-Y 1–1.5 and H-Y 3–4 in the
left affected side (P = 0.005). Correlation analysis also
showed that the PD-Monitor score was related with
modified H-Y stage in the left side (r = 0.452, P = 0.001).
Partial correlation analysis further revealed this positive
correlation still existed even after controlling age, gen-
der, disease duration and LEDD (r = 0.388, P = 0.008).
Discussion
This is the first study to validate evolutionary algorithms
in a Chinese population. In our study, we included dif-
ferent grades of bradykinesia from 0 to 3 rated by
MDS-UPDRS FT item, and found a strong correlation
between PD-Monitor FT objective scores and MDS-
UPDRS FT subjective scores. Furthermore, we demon-
strated that using different cutoff values, PD-Monitor
could discriminate different severity of bradykinesia
from normality with high accuracy, sensitivity and speci-
ficity, which not only confirmed the results of the first
study on PD-Monitor which only included PD patients
Table 2 PD-Monitor FT objective score differentiated PD from NC
Right side Left side
AUC Sens % Spec % Acc % Cutoff AUC Sens % Spec % Acc % Cutoff
All PD vs.NC
0.976 94.6 91.8 93.5 0.018 0.959 85.1 91.8 88.6 0.072
Subgroups of PD vs. NC
FT 1 vs.NC 0.952 94.7 89.8 89.7 0.005 0.898 65.5 89.8 81.0 0.060
FT 2 vs.NC 0.979 89.5 98.0 94.3 0.118 0.996 96.0 98.0 97.3 0.122
FT 3 vs.NC 0.995 100 98.0 98.5 0.122 1.000 100 100 100 0.308
H-Y 1 vs.NC 0.963 94.4 91.8 92.5 0.029 0.899 66.7 98.0 89.6 0.141
AUC the area under the receiver operating characteristic curve, Sens Sensitivity, Spec Specificity, Acc accuracy, PD Parkinson’s disease, NC normal controls, FT finger
tapping, H-Y modified Hoehn and Yahr stage
Fig. 3 PD-Monitor FT objective score detected different severity of bradykinesia. The ROC curves illustrated strong separation between overall PD
and NC, as well as between each subgroup (FT = 1, FT = 2, FT = 3) of PD and NC. a Right affected side, All PD vs. NC: AUC = 0.976, accuracy =
93.5%, sensitivity = 94.6%, specificity = 91.8%, cutoff = 0.018; PD (FT = 1) vs. NC: AUC = 0.952, accuracy = 89.7%, sensitivity = 94.7%, specificity =
89.8%, cutoff = 0.005; PD (FT = 2) vs. NC: AUC = 0.979, accuracy = 94.3%, sensitivity = 89.5%, specificity = 98.0%, cutoff = 0.118; PD (FT = 3) vs. NC:
AUC = 0.995, accuracy = 98.5%, sensitivity = 100%, specificity = 98.0%, cutoff = 0.122; all with P = 0.000. b Left affected side: All PD vs. NC: AUC =
0.959, accuracy = 88.6%, sensitivity = 85.1%, specificity = 91.8%, cutoff = 0.072; PD (FT = 1) vs. NC: AUC = 0.898, accuracy = 81.0%, sensitivity = 65.5%,
specificity = 89.8%, cutoff = 0.060; PD (FT = 2) vs. NC: AUC = 0.996, accuracy = 97.3%, sensitivity = 96.0%, specificity = 98.0%, cutoff = 0.122; PD
(FT = 3) vs. NC: AUC = 1.000, accuracy = 100%, sensitivity = 100%, specificity = 100%, cutoff = 0.308; all with P = 0.000. PD, Parkinson’s disease; NC,
normal controls; FT, finger tapping; ROC, Receiver operating characteristics; AUC, area under the ROC curve
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with slight bradykinesia [9, 15], but also provided an evi-
dence for a wider application of the device assessing slight
to moderate bradykinesia. It is also worthy to note that in
our present study, all participants were right-hand domin-
ant and the PD-Monitor FT data from the affected limbs
of patients were compared with that of the same sides
from NC, making the design more rigorous than the first
study [9, 15]. Indeed, in our study, different cutoff values
were found between two hand sides for identifying the
same degree of subjective bradykinesia. Overall, the cutoff
values were larger in the left hand side than that in the
right hand side based on their similar specificity, whereas
the sensitivity compromised in the left sides.
Our present study also demonstrated that PD-Monitor
could differentiate PD from ET without bradykinesia
with high accuracy, sensitivity and specificity. However,
this discrimination seemed to rely on the existence of
bradykinesia itself, rather than the different nature of
bradykinesia, since the present EAs could not differenti-
ate the FT bradykinesia pattern of ET from that of PD.
Slower movements could be observed in certain ET pa-
tients [5, 17–19], whereas reduction in amplitudes or
freezing has not been reported in ET, which indicated
that bradykinesia features of ET was probably different
from that of PD. Because the EA used in this study was
trained by using FT kinetics recordings of PD and NC
[9], not PD and ET with bradykinesia, it would limit its
capability of differentiating various bradykinesia patterns
of FT.
Furthermore, our study suggested that PD-Monitor
had potential to be used for diagnosis of early stage PD
with high accuracy, sensitivity and specificity in the right
dominant affected side. This has not been reported be-
fore, but it was consistent with the results that it could
accurately detect slight bradykinesia, which was found
both in our present study and the previous study [9, 15].
A positive correlation between PD-Monitor score and
modified H-Y stage was also found in our cohort. The
correlation of FT objective assessment and disease severity
in PD was also reported in previous studies [20–22], in
which they used UPDRS motor scores, a more reliable
marker to assess the disease severity. However, in our study,
this correlation was only found in the left affected side. The
precise reason is unknown, but small samples of subgroups
might be one factor affecting the statistical power.
Taking together, our study presented the value of
PD-Monitor in clinical practice. Other research groups
have also explored computer-based systems and wear-
able sensors to quantitatively assess parkinsonism related
symptoms including bradykinesia [23–28] and dyskinesia
[29, 30]. Different tasks were used to assess bradykinesia
such as FT [27], hand movements [28], toe tapping and
leg agility [29]. In general, most of them only focus on
gross movement features, such as mean amplitude and
velocity, and construct the classifier through linear com-
binations of those features [26]. In contrast, EAs pro-
duce dynamical classifiers which are particularly useful
for the problems where classification involves complex,
dynamical, and poorly understood modeling processes
[9]. In this regard, EAs appear to be a preferred method
used in neurological diagnosis.
Limitations of this study are as follows. First of all, the
present study was a cross-section study, and the raters
were not blind to the diagnosis of subjects. Secondly, the
PD patients assessed in this study were allowed to take
their usual medication. Although it did not affect the
evaluation of relationship between PD-Monitor FT score
and MDS-UPDRS FT score, it might impact on the rela-
tionship between PD-Monitor FT score and disease sever-
ity. Finally, due to the small sample size of ET with
bradykinesia, it is too early to conclude that PD-Monitor
could not differentiate ET with bradykinesia from PD. In
the future, more research is needed to test the differential
capability of PD-Monitor for various bradykinesia patterns
of FT. The spectrum of diseases could include ET with
bradykinesia, atypical parkinsonian syndromes, or other
neurological diseases with slowness of finger movements
such as stroke or motor neuron diseases.
Conclusions
Our study demonstrates that a simple to use device
employing classifiers derived from EAs could not only
be used to accurately measure different severity of bra-
dykinesia in PD, but also has the potential to differenti-
ate early stage PD from normality.
Fig. 4 PD-Monitor FT objective score could potentially discriminate
early stage PD from NC. The ROC curves illustrated a strong separation
between the early PD patients (H-Y 1) and NC. Right affected side:
AUC = 0.963, P = 0.000, accuracy = 92.5%, sensitivity = 94.4%, specificity
= 91.8%, cutoff value = 0.029; Left affected side: AUC = 0.899, P = 0.000,
accuracy = 89.6%, sensitivity = 66.7%, specificity = 98.0%, cutoff value =
0.141. PD, Parkinson’s disease; NC, normal controls; H-Y, Hoehn and
Yahr stage; ROC, Receiver operating characteristics; AUC, area under
the ROC curve
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